Abstract. The syndrome of combined pulmonary fibrosis and emphysema (CPFE) has been characterized by severely impaired gas exchange and poor survival. However, the clinical features of patients with lung cancer plus CPFE have remained elusive. The present study performed a retrospective analysis to examine the clinical characteristics and outcome of surgically resected patients with lung cancer plus CPFE. Among 831 patients with primary lung cancer who underwent surgical resection, 23 patients (2.8%) were diagnosed with CPFE and 9 patients (1.1%) with solely idiopathic pulmonary fibrosis (IPF). Thirty-five patients were stratified as the solely emphysema group with adjustment of the pathological stage. The clinicopathological characteristics of patients in the CPFE group and their outcomes were evaluated and compared with those with the solely IPF or solely emphysema groups. Within the CPFE group, no significant differences in survival between patients with post-operative acute exacerbation (AE; n=3) and those without AE (n=20) were noted; however, in the solely IPF group, patients with post-operative AE (n=4) had a significantly shorter survival than those without AE (n=5; P=0.022). The 5-year survival rate of patients in the CPFE, solely IPF and solely emphysema groups was 22, 22 and 58%, respectively. Furthermore, the CPFE and solely IPF groups showed a significantly shorter survival than the solely emphysema group (P=0.001 and 0.011, respectively). In conclusion, surgically resected lung cancer patients with CPFE had poor survival, which was, in contrast to that of lung cancer patients with solely IPF, not affected by AE.
Introduction
The syndrome of combined pulmonary fibrosis and emphysema (CPFE) has been suggested to be a clinically important phenotype of pulmonary fibrosis (1). Cottin et al (1) defined CPFE as a distinct condition, with characteristic features in the chest computed tomography (CT) image that include emphysema in the upper pulmonary region concomitant with parenchymal fibrosis in the lower region. The syndrome is characterized by sub-normal spirometry, severely impaired gas exchange, high prevalence of pulmonary hypertension and poor survival (2-4). Mejía et al (3) reported that survival of CPFE patients was poorer compared with that of patients with idiopathic pulmonary fibrosis (IPF) alone and that pulmonary hypertension in CPFE patients was an independent predictor of mortality. Previous studies have indicated that CPFE patients have a significantly increased risk of lung cancer compared with patients with chronic obstructive pulmonary disease (COPD) or IPF alone (1, 4, 5) . Post-operative acute exacerbation (AE) of interstitial lung disease in patients with lung cancer is associated with a high mortality rate (43.9%) (6) . However, the clinical features and prognosis of patients with lung cancer and CPFE have remained elusive. The present study performed a retrospective analysis to determine the prevalence, clinical characteristics and outcome of patients with surgically resected lung cancer and CPFE. In addition, differences between the clinical features and outcomes of patients with lung cancer and CPFE, solely IPF and solely emphysema were assessed, and the impact of post-operative AE on patient survival was determined.
Patients and methods
Patient data. Of 831 consecutive patients with primary lung cancer who underwent surgical resection at Toho University School of Medicine between June 2004 to December 2014, 23 patients with CPFE (2.8%) were retrospectively reviewed by the present study. CPFE was diagnosed by chest high-resolution computed tomography (HRCT) images showing emphysema involving >25% of both upper lobes and a usual interstitial pneumonia (UIP) pattern of fibrosis in the lower lobes (Fig. 1) Measurement of serum marker levels. As indicators of UIP, the serum levels of Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) were determined prior to surgery. Serum KL-6 (normal levels, <500 U/ml) was measured using an enzyme-linked immunosorbent assay (ELISA; ELTEST KL-6 kit; Eisai Co., Tokyo, Japan) and serum SP-D (normal levels, <110 ng/ml) was measured using an ELISA kit (SP-D kit YAMASA EIA II, Yamasa Corp., Tokyo, Japan).
Chest CT. Chest CT was performed using a helical CT scanner (Aquilion 16; Toshiba, Tokyo, Japan). Routine scanning of the entire lung was performed with a slice thicknesses of 5-10 mm, followed by HRCT imaging at full inspiration with 1-2-mm sections (120 kVp; 300 mA; pitch, 1.0). For all patients, HRCT images were captured with a window setting appropriate for the lungs (window level from -600 Hounsfield units; width from 1,600 Hounsfield units).
Pulmonary function testing. Spirometry and measurement of the diffusing capacity of the lung for carbon monoxide (DLco) were performed using a pulmonary function test system (Chestac-33; CHEST Co. Ltd., Tokyo, Japan). The DLco was measured using the single-breath technique. The pulmonary function tests were performed by two technicians according to the recommendations of the American Thoracic Society (9).
Statistical analysis. All statistical analyses were performed using the JMP version 10.0.0 statistical software package 
Results
Patient characteristics. The characteristics of the patients are shown in Table I . All patients in the CPFE or solely IPF groups were male, while five patients in the emphysema group were female (14%). The results of the pulmonary function tests, including the percent vital capacity (%VC) or forced expiratory volume in one second as percent of forced vital capacity (FEV 1.0 %) of the patients in the CPFE group were almost normal, while patients in the solely IPF group had a slightly decreased %VC and patients in the solely emphysema had a decreased FEV 1.0 % and %FEV 1.0 . However, the percent predicted DLco (%DLco) of the patients in the CPFE group was noticeably low. The predominant histology of lung tumors in the CPFE group was squamous-cell carcinoma and the majority of patients had advanced-stage disease.
No statistically significant differences were observed in the mean age, smoking status, %VC, FEV 1.0 %, %DLco, type of surgical procedure, histological type and pathological stage of lung cancer between patients in the CPFE with AE group and those in the CPFE without AE group (Table II) .
Survival. Survival in the CPFE and solely IPF groups is significantly lower compared with that in the solely emphysema group, while AE does not affect survival in the CPFE group. The 3-and 5-year survival rate in the CPFE group was 38 and 22%, respectively. The Kaplan-Meier survival curves for patients in the CPFE group showed no significant differences between patients with AE and those without AE (P=0.084; Fig. 2A ).The 3-year survival rate in the CPFE with AE group was 33% and that in the CPFE without AE group was 38%. The survival time in the solely IPF with AE group was significantly shorter compared with that in the solely IPF without AE group (5.0 vs. 24.4 month P= 0.022, log-rank test; Fig. 2B ). The 5-year survival rate of patients in the CPFE, solely IPF and solely emphysema groups was 22, 22 and 58%, respectively. Furthermore, the CPFE and solely IPF groups showed a significantly shorter survival than the solely emphysema group (P=0.001 and 0.011, respectively; Fig. 3) ; however, no significant difference was determined between the CPFE and solely IPF group (P=0.924. In Tables III  and IV , data on the fatal cases in the CPFE with AE and CPFE without AE groups are summarized, respectively. In the CPFE with AE group, two patients succumbed to post-operative AE after 2 months and one patient succumbed after 36 months (Table III) . In the CPFE without AE group, four patients succumbed to lung cancer and two succumbed to other cancer types. Furthermore, the cause of mortality was chemotherapy-induced AE in three patients (carboplatin/ etoposide, carboplatin/paclitaxel/bevacizumab, gefitinib), pneumonia in another three patients and myocardial infarction in one patient (Table IV) .
Discussion
As first defined by Cottin et al (1) (2) reported that in a cohort with CPFE, Figure 1 . High-resolution computed tomography scan of a patient with combined pulmonary fibrosis and emphysema, who presented with an enlarged nodule in the right upper lobe (left). The image shows emphysema involving >25% of both upper lobes and a usual interstitial pneumonia pattern of fibrosis in the lower lobes (right). (4) suggested that the following factors or diagnostic errors may account for the differential outcomes of CPFE and IPF alone: i) The presence of primary lung cancer, ii) disease severity based on distributions or extension of fibrosis and/or emphysema, iii) possible confusion between chronic fibrotic interstitial pneumonia and fibrotic non-specific interstitial pneumonia, iv) the difficulty in radiological discrimination between emphysema with non-specific fibrosis and IPF (for example, wall thickening due to emphysematous may be mistaken for honeycomb cysts). The study also reported that patients with CPFE had a poor outcome even in patients without the complication of lung cancer at the initial visit, with median survival time of 28 months in their subgroup analysis (4). However, these findings suggested Kaplan-Meier estimates of overall survival of lung cancer patients with combined pulmonary fibrosis and emphysema divided into those who developed post-operative AE (n=3) and those who did not (n=20). The 3-year survival rates were 33% in patients with AE and 38% in those without AE, while differences were not significant (P= 0.084, log-rank test). (B) Kaplan-Meier estimates of overall survival of lung cancer patients with solely IPF divided into those who developed AE (n=4) and those who did not (n=5). The survival time of patients with IPF and AE was significantly shorter compared with that of patients without AE (P= 0.022, log-rank test). OS, overall survival; AE, acute exacerbation; IPF, idiopathic pulmonary fibrosis. Figure 3 . OS of patients with CPFE, solely IPF and solely Em. The 5-year survival rates were 22, 22 and 58%, respectively. Patients with CPFE or solely IPF showed a significantly poor survival compared with those with solely Em (P=0.001 and 0.011, respectively). OS, overall survival; Em, emphysema; IPF, idiopathic pulmonary fibrosis; CPFE, combined pulmonary fibrosis and emphysema.
that CPFE is associated with a poor prognosis, which was in accordance with the present study, which reported poor 3-and 5-year survival rates of 38 and 22%, respectively for resected CPFE patients with lung cancer. Of note, a number of CPFE patients in the present study succumbed to AE or lung cancer recurrence. However, as shown in Table I , the pulmonary function of these patients was almost normal, except for the DLco results. CPFE may be difficult to detect by the pulmonary function tests that are usually performed for patients. DLco is important to detect CPFE and to consider the potential risk of chemotherapy for the patients with CPFE. AE is an important negative prognostic factor for surgically resected lung cancer patients with interstitial lung disease (ILD). Sato et al (6) reported that AE occurred in 9.3% of surgically resected lung cancer patients with ILD, accounting for a mortality rate of 43.9%. They also identified the following independent risk factors for AE: Surgical procedures (wedge resection, lobectomy/segmentectomy, bilobectomy/pneumonectomy), male gender, history of exacerbation, pre-operative steroid use, elevated serum KL-6 levels (≥1,000 U/ml), appearance of UIP in the CT spectrum and reduced percentage of predicted vital capacity. Although two of the patients in the present study matched the risk factors of male gender and CT findings, it was not possible to determine whether these or any other factors were associated with CPFE due to the low patient number. In the present study, only three cases with post-operative AE were included and no statistically significant differences in clinicopathological parameters or survival rates between patients with AE and those without AE were identified. Previous studies have reported that surgically resected lung cancer patients with IPF who developed post-operative AE had a poorer survival compared with those without AE (13) (14) (15) (16) , which was in line with the findings of the present study regarding the solely IPF with AE and the solely IPF without AE groups. The finding that AE did not affect survival in CPFE patients in the present study may be due to inclusion of cases of small-cell carcinoma in the CPFE without AE group, in addition to the small sample size. Therefore, additional analysis is required, including the comparison of the molecular characteristics of lung cancer patients with CPFE and those with lung cancer and IPF.
The present study had several limitations. There were intrinsic limitations associated with the data, as they were collected and reviewed retrospectively. In addition, the study cohort was small, and further studies on larger populations are required to validate the results. In conclusion, the present study revealed that lung cancer patients with CPFE had poor survival, which was comparable with that of lung cancer patients with IPF. Numerous patients with lung cancer and CPFE presented with post-operative recurrence of lung cancer or developed AE or pneumonia. The present study contributed to the current understanding of the clinical and pathophysiological features as well as the outcome of lung cancer patients with CPFE, which requires to be confirmed and further elucidated by larger-scale studies.
